Share this article on:

TOUCH® PRO Study: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction: P-65

Rubin, David1; Nag, Arpita2; Taylor, Lori3; Hogge, Gary4; Kane, Sunanda5; Lewis, James6; Panaccione, Remo7; Colombel, Jean-Frédéric8

Inflammatory Bowel Diseases: December 2012 - Volume 18 - Issue - p S42
Abstracts from the 2012 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation's National Clinical & Research Conference December 13–15, 2012 Hollywood, Florida: Clinical Poster Presentations

1University of Chicago Medicine, Chicago, IL, USA,

2Elan Pharmaceuticals, South San Francisco, CA, USA,

3Elan Pharmaceuticals, Inc., South San Francisco, CA, USA,

4GSH Biomedical Consulting, San Francisco, CA, USA,

5Mayo Clinic, Rochester, Minnesota, USA,

6University of Pennsylvania, Philadelphia, PA, USA,

7University of Calgary, Calgary, AB, Canada,

8 Hopital Huriez, CHRU, Lille, Nord, France

© Crohn's & Colitis Foundation of America, Inc.